What is the assessment and plan for a 54-year-old female with a past medical history (PMH) of Bipolar I disorder, presenting with signs of a potential manic episode, non-adherence to prescribed medications, Seroquel (quetiapine) and Lithium, and a history of multiple hospitalizations for manic episodes?

Assessment and Plan for Acute Manic Episode with Medication Non-Adherence

Assessment

This is a 54-year-old female with Bipolar I disorder presenting with clear signs of an acute manic episode triggered by 2 months of medication non-adherence to her previously effective regimen of lithium 900mg and quetiapine 200mg. 1, 2, 3

Clinical Features Supporting Acute Mania:

• Decreased need for sleep (not sleeping for 10 days) 2
• Increased goal-directed activity (watching excessive TV, singing) 2
• Disorganized thought content ("saying weird things") 2
• Pattern consistent with previous manic episodes requiring hospitalization 1
• Psychosocial stressors present (family financial stress, college applications) 1

Critical Risk Factors:

• History of multiple psychiatric hospitalizations (3 prior admissions, most recent in documented date) 1
• Documented medication non-adherence (2 months without treatment) 1, 4
• Previous adverse reaction to aripiprazole LAI (akathisia and acute dystonia) - this eliminates aripiprazole as a treatment option 1
• Patient pursuing alternative treatments (acupuncture with provider claiming to "cure" bipolar disorder) represents ongoing adherence risk 5

Severity Assessment:

This represents a moderate-to-severe manic episode requiring immediate intervention, likely necessitating voluntary psychiatric admission given the duration of symptoms (10 days), complete medication non-adherence, and pattern matching previous hospitalizations. 1, 6

---

Plan

Immediate Pharmacological Management

Restart the patient's previously effective medication regimen of lithium 900mg daily and quetiapine 200mg at bedtime immediately, as these medications successfully controlled her symptoms before and represent first-line evidence-based treatment for acute mania. 1, 4, 2, 3

Lithium Reinitiation:

• Resume lithium 900mg daily (her previous maintenance dose) 4, 2
• Obtain stat lithium level to confirm she is at zero from 2 months non-adherence 4
• Target therapeutic level of 0.8-1.2 mEq/L for acute mania treatment 1, 4
• Check lithium level in 5 days after reinitiation, then weekly until stable 4
• Baseline labs required immediately: comprehensive metabolic panel (BUN, creatinine, calcium), TSH, CBC, urinalysis, pregnancy test 4, 7
• Lithium produces normalization of manic symptoms within 1-3 weeks 2

Quetiapine Reinitiation:

• Resume quetiapine 200mg at bedtime (her previous effective dose) 1, 3
• Quetiapine is FDA-approved for acute manic episodes in bipolar I disorder as monotherapy and as adjunct to lithium 3, 8
• The combination of lithium plus quetiapine is more effective than either agent alone for acute mania 1
• Address her sedation concerns: Explain that initial sedation typically improves after 1-2 weeks as tolerance develops, and that sleeping 13 hours was likely related to undertreated depression or excessive dosing that can be adjusted 3, 8

Adjunctive Acute Management

Add lorazepam 1-2mg every 4-6 hours as needed for acute agitation, as benzodiazepines combined with antipsychotics provide superior control of manic agitation compared to either agent alone. 1

• Maximum daily dose: 6mg lorazepam equivalent 1
• Duration: Taper and discontinue within 7-14 days as quetiapine and lithium take effect 1
• Avoid long-term benzodiazepine use due to tolerance and dependence risk 1

Monitoring Protocol

First Week:

• Daily clinical assessment of manic symptoms, sleep, agitation, and medication adherence 1
• Lithium level on day 5, then adjust dose if needed 4
• Monitor for lithium toxicity signs: tremor, confusion, ataxia, nausea, diarrhea 4
• Baseline metabolic monitoring: weight, BMI, waist circumference, blood pressure, fasting glucose, lipid panel 1

Ongoing Monitoring (Every 3-6 Months):

• Lithium levels, renal function (BUN, creatinine), thyroid function (TSH), urinalysis 4, 7
• Metabolic parameters: BMI monthly for 3 months then quarterly; blood pressure, fasting glucose, lipids at 3 months then yearly 1
• CBC and hepatic function if any clinical concerns arise 4

Disposition and Level of Care

Strongly recommend voluntary psychiatric hospitalization for the following reasons: 1, 6

• 10-day duration of untreated mania with progressive symptoms
• Complete medication non-adherence for 2 months requiring supervised medication reinitiation
• Pattern matching 3 previous hospitalizations for similar presentations
• Need for close monitoring during lithium and quetiapine reinitiation
• Safety concerns with impaired judgment and disorganized thinking

If patient refuses hospitalization, consider intensive outpatient program (IOP) or partial hospitalization program (PHP) with: 5

• Daily visits for first week to monitor response and ensure medication adherence
• Family/relative involvement in medication supervision (third-party dispensing)
• Clear return precautions: worsening insomnia, increased agitation, psychotic symptoms, suicidal ideation
• Emergency contact information provided to family

Addressing Medication Adherence Barriers

Critical conversation required about sedation concerns and alternative treatment beliefs: 1, 5

• Validate her experience of excessive sedation (13 hours sleep) but explain this was likely multifactorial (depression, possible overmedication, timing of doses) 5
• Propose dose timing adjustments if sedation recurs: take quetiapine earlier in evening, consider splitting lithium to twice daily 4
• Psychoeducation about bipolar disorder: This is a chronic, recurrent illness requiring lifelong treatment; 90% of patients who stop lithium relapse, often within 6 months 1, 4
• Address alternative treatment: Acupuncture may be complementary but cannot replace evidence-based pharmacotherapy; no provider can "cure" bipolar disorder 5
• Discuss consequences of non-adherence: Each manic episode can cause neurobiological changes, worsen prognosis, and increase risk of future episodes 6, 5

Psychosocial Interventions

Initiate or resume psychotherapy as adjunct to pharmacotherapy: 1, 5

• Cognitive-behavioral therapy (CBT) has strong evidence for bipolar disorder 1
• Family psychoeducation involving her relative to improve medication supervision and early warning sign recognition 1
• Address psychosocial stressors: Family financial concerns and college applications are clear triggers 1

Ensure outpatient psychiatry follow-up within 1-2 weeks of discharge or ED visit: 1

• Verify she has established psychiatrist (reports seeing provider monthly)
• Schedule urgent follow-up appointment before discharge
• Provide crisis resources: 988 Suicide & Crisis Lifeline, local crisis center

Contraindications and Medications to Avoid

Do NOT use aripiprazole in any formulation given her documented history of akathisia and acute dystonia with Abilify Maintena LAI. 1

Do NOT use antidepressant monotherapy as this can trigger mania, rapid cycling, or mood destabilization in bipolar disorder. 1, 9

Avoid typical antipsychotics (haloperidol, fluphenazine) due to high risk of extrapyramidal symptoms and tardive dyskinesia. 1

Common Pitfalls to Avoid

• Inadequate treatment duration: Maintenance therapy must continue for minimum 12-24 months after stabilization; many patients require lifelong treatment 1, 4
• Premature discontinuation: Over 90% of adolescents/young adults who stop lithium relapse versus 37.5% who remain adherent 1
• Insufficient lithium levels: Must achieve 0.8-1.2 mEq/L for acute mania; subtherapeutic levels are ineffective 4
• Ignoring metabolic monitoring: Quetiapine carries risk of weight gain, diabetes, and dyslipidemia requiring regular screening 1
• Failing to address adherence barriers: Her sedation concerns and belief in alternative cure must be directly confronted with education and dose adjustments 5
• Overlooking family involvement: Her relative is clearly invested and should be engaged in treatment planning and medication supervision 1

Expected Timeline

• Days 1-7: Acute symptom management with benzodiazepines; begin seeing improvement in sleep and agitation 1, 2
• Weeks 1-3: Progressive reduction in manic symptoms as lithium reaches therapeutic levels and quetiapine takes full effect 2
• Week 4: Reassess response; if inadequate improvement despite therapeutic lithium levels and medication adherence, consider adding or switching to alternative mood stabilizer (valproate) 1, 7
• Months 3-6: Stabilization phase with continued monitoring and psychotherapy 1
• Beyond 6 months: Maintenance phase with ongoing treatment for minimum 12-24 months, likely longer given her multiple prior episodes 1, 4